InTech uses cookies to offer you the best online experience. By continuing to use our site, you agree to our Privacy Policy.

Medicine » Oncology » "Research on Melanoma - A Glimpse into Current Directions and Future Trends", book edited by Mandi Murph, ISBN 978-953-307-293-7, Published: September 12, 2011 under CC BY-NC-SA 3.0 license. © The Author(s).

Chapter 5

Low-Anticoagulant Heparins in the Treatment of Metastasis

By Narayanam V. Rao, Glenn D. Prestwich, John R. Hoidal and Thomas P. Kennedy
DOI: 10.5772/19859

  1. R. Abe, Y. Fujita, S. Yamagishi, 2007Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini Rev Med Chem, 76649661Print) 1389-5575 (Linking)

  2. R. Abe, T. Shimizu, H. Sugawara, H. Watanabe, H. Nakamura, H. Choei, N. Sasaki, S. Yamagishi, M. Takeuchi, H. Shimizu, 2004Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol, 1222461467X (Print) 0022-202X (Linking)

  3. G. M. Arepally, T. L. Ortel, 2010Heparin-induced thrombocytopenia. Annu Rev Med, 617790X (Electronic) 0066-4219 (Linking)

  4. W. H. Barry, X. Q. Zhang, M. E. Halkos, J. Vinten-Johansen, N. Saegusa, K. W. Spitzer, N. Matsuoka, M. Sheets, N. V. Rao, T. P. Kennedy, 2010Nonanticoagulant heparin reduces myocyte Na+ and Ca2+ loading during simulated ischemia and decreases reperfusion injury. Am J Physiol Heart Circ Physiol, 2981H102H111Electronic) 0363-6135 (Linking)

  5. M. Borgenstrom, A. Warri, K. Hiilesvuo, R. Kakonen, S. Kakonen, L. Nissinen, M. Pihlavisto, A. Marjamaki, I. Vlodavsky, A. Naggi, G. Torri, B. Casu, T. Veromaa, M. Salmivirta, K. Elenius, 2007O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. Semin Thromb Hemost, 335547556Print) 0094-6176 (Linking)

  6. L. Borsig, 2010Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb Res, 125Suppl 2,S66S71Electronic) 0049-3848 (Linking)

  7. L. Borsig, R. Wong, J. Feramisco, D. R. Nadeau, N. M. Varki, A. Varki, 2001Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A, 98633523357Print) 0027-8424 (Linking)

  8. L. Borsig, R. Wong, R. O. Hynes, N. M. Varki, A. Varki, 2002Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci U S A, 99421932198Print) 0027-8424 (Linking)

  9. M. L. Brezniceanu, K. Volp, S. Bosser, C. Solbach, P. Lichter, S. Joos, M. Zornig, 2003HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J, 171012951297Electronic) 0892-6638 (Linking)

  10. A. D. Cardin, H. J. Weintraub, 1989Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis, 912132Print) 0276-5047 (Linking)

  11. B. Casu, A. Naggi, G. Torri, 2010Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol, 296442452Electronic) 0945-053X (Linking)

  12. B. Casu, I. Vlodavsky, R. D. Sanderson, 2008Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb, 363-4195203Electronic) 1424-8832 (Linking)

  13. M. S. Diamond, R. Alon, C. A. Parkos, M. T. Quinn, T. A. Springer, 1995Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1). J Cell Biol, 130614731482Print) 0021-9525 (Linking)

  14. R. Donato, 1999Functional roles of S100 proteins, calcium-binding proteins of the EF-hand type. Biochim Biophys Acta, 14503191231Print) 0006-3002 (Linking)

  15. R. Donato, 2001S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol, 337637668Print) 1357-2725 (Linking)

  16. R. Donato, G. Sorci, F. Riuzzi, C. Arcuri, R. Bianchi, F. Brozzi, C. Tubaro, I. Giambanco, 2009S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta, 1793610081022Print) 0006-3002 (Linking)

  17. Xda. E. Dong, N. Ito, M. T. Lotze, R. A. Demarco, P. Popovic, S. H. Shand, S. Watkins, S. Winikoff, C. K. Brown, D. L. Bartlett, H. J. Zeh, 3rd , 2007High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother, 306596606Print) 1524-9557 (Linking)

  18. I. E. Dumitriu, P. Baruah, A. A. Manfredi, M. E. Bianchi, P. Rovere-Querini, 2005HMGB1: guiding immunity from within. Trends Immunol, 267381387Print) 1471-4906 (Linking)

  19. J. E. Ellerman, C. K. Brown, M. de Vera, H. J. Zeh, T. Billiar, A. Rubartelli, M. T. Lotze, 2007Masquerader: high mobility group box-1 and cancer. Clin Cancer Res, 131028362848Print) 1078-0432 (Linking)

  20. A. Fryer, Y. C. Huang, G. Rao, D. Jacoby, E. Mancilla, R. Whorton, C. A. Piantadosi, T. Kennedy, J. Hoidal, 1997Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther, 2821208219Print) 0022-3565 (Linking)

  21. Y. Gao, M. Wei, S. Zheng, X. , S. Hao, X. Zeng, 2006Chemically modified heparin inhibits the in vitro adhesion of nonsmall cell lung cancer cells to P-selectin. J Cancer Res Clin Oncol, 1324257264Print) 0171-5216 (Linking)

  22. A. Goerner, 1930The influence of anti-clotting agents on transplantation and growth of tumor tissue. J Lab Clin Med, 16369372

  23. L. E. Hanford, J. J. Enghild, Z. Valnickova, S. V. Petersen, L. M. Schaefer, T. M. Schaefer, T. A. Reinhart, T. D. Oury, 2004Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem, 279485001950024Print) 0021-9258 (Linking)

  24. R. Harpio, R. Einarsson, 2004S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem, 377512518Print) 0009-9120 (Linking)

  25. R. J. Hettiarachchi, S. M. Smorenburg, J. Ginsberg, M. Levine, M. H. Prins, H. R. Buller, 1999Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb Haemost, 822947952Print) 0340-6245 (Linking)

  26. J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, J. E. Dalen, 2001Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 1191Suppl, 64S94SPrint) 0012-3692 (Linking)

  27. M. A. Hofmann, S. Drury, C. Fu, W. Qu, A. Taguchi, Y. Lu, C. Avila, N. Kambham, A. Bierhaus, P. Nawroth, M. F. Neurath, T. Slattery, D. Beach, J. Mc Clary, M. Nagashima, J. Morser, D. Stern, A. M. Schmidt, 1999RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell, 977889901Print) 0092-8674 (Linking)

  28. H. L. Hsieh, B. W. Schafer, N. Sasaki, C. W. Heizmann, 2003Expression analysis of S100 proteins and RAGE in human tumors using tissue microarrays. Biochem Biophys Res Commun, 3072375381X (Print) 0006-291X (Linking)

  29. H. J. Huttunen, C. Fages, J. Kuja-Panula, A. J. Ridley, H. Rauvala, 2002Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res, 621648054811Print) 0008-5472 (Linking)

  30. H. J. Huttunen, C. Fages, H. Rauvala, 1999Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem, 274281991919924Print) 0021-9258 (Linking)

  31. H. J. Huttunen, J. Kuja-Panula, G. Sorci, A. L. Agneletti, R. Donato, H. Rauvala, 2000Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem, 275514009640105Print) 0021-9258 (Linking)

  32. T. Irimura, M. Nakajima, G. L. Nicolson, 1986Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells. Biochemistry, 251853225328Print) 0006-2960 (Linking)

  33. H. Ishiguro, N. Nakaigawa, Y. Miyoshi, K. Fujinami, Y. Kubota, H. Uemura, 2005Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. Prostate, 64192100Print) 0270-4137 (Linking)

  34. B. Kaeffer, C. Benard, M. Lahaye, H. M. Blottiere, C. Cherbut, 1999Biological properties of ulvan, a new source of green seaweed sulfated polysaccharides, on cultured normal and cancerous colonic epithelial cells. Planta Med, 656527531Print) 0032-0943 (Linking)

  35. O. Kepp, A. Tesniere, F. Schlemmer, M. Michaud, L. Senovilla, L. Zitvogel, G. Kroemer, 2009Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis, 144364375X (Electronic) 1360-8185 (Linking)

  36. Y. J. Kim, L. Borsig, N. M. Varki, A. Varki, 1998P-selectin deficiency attenuates tumor growth and metastasis. Proc Natl Acad Sci U S A, 951693259330Print) 0027-8424 (Linking)

  37. A. Koenig, K. Norgard-Sumnicht, R. Linhardt, A. Varki, 1998Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest, 1014877889Print) 0021-9738 (Linking)

  38. M. Kragh, L. Binderup, Hjarnaa. P. J. Vig, E. Bramm, K. B. Johansen, Petersen. C. Frimundt, 2005Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep, 14199104X (Print) 1021-335X (Linking)

  39. M. Kragh, F. Loechel, 2005Non-anti-coagulant heparins: a promising approach for prevention of tumor metastasis (review). Int J Oncol, 27411591167Print) 1019-6439 (Linking)

  40. H. Kuniyasu, N. Oue, A. Wakikawa, H. Shigeishi, N. Matsutani, K. Kuraoka, R. Ito, H. Yokozaki, W. Yasui, 2002Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol, 1962163170Print) 0022-3417 (Linking)

  41. F. Lapierre, K. Holme, L. Lam, R. J. Tressler, N. Storm, J. Wee, R. J. Stack, J. Castellot, D. J. Tyrrell, 1996Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology, 63355366Print) 0959-6658 (Linking)

  42. E. Leclerc, G. Fritz, S. W. Vetter, C. W. Heizmann, 2009Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta, 179369931007Print) 0006-3002 (Linking)

  43. R. Lever, C. P. Page, 2002Novel drug development opportunities for heparin. Nat Rev Drug Discov, 12140148Print) 1474-1776 (Linking)

  44. X. Ling, N. Sakashita, M. Takeya, R. Nagai, S. Horiuchi, K. Takahashi, 1998Immunohistochemical distribution and subcellular localization of three distinct specific molecular structures of advanced glycation end products in human tissues. Lab Invest, 781215911606Print) 0023-6837 (Linking)

  45. C. D. Logsdon, M. K. Fuentes, E. H. Huang, T. Arumugam, 2007RAGE and RAGE ligands in cancer. Curr Mol Med, 78777789Print) 1566-5240 (Linking)

  46. M. T. Lotze, K. J. Tracey, 2005High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol, 54331342Print) 1474-1733 (Linking)

  47. L. Lundin, H. Larsson, J. Kreuger, S. Kanda, U. Lindahl, M. Salmivirta, L. Claesson-Welsh, 2000Selectively desulfated heparin inhibits fibroblast growth factor-induced mitogenicity and angiogenesis. J Biol Chem, 275322465324660Print) 0021-9258 (Linking)

  48. Y. Q. , J. G. Geng, 2000Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow. J Immunol, 1651558565Print) 0022-1767 (Linking)

  49. A. Maraveyas, M. J. Johnson, Y. P. Xiao, S. Noble, 2010Malignant melanoma as a target malignancy for the study of the anti-metastatic properties of the heparins. Cancer Metastasis Rev, 294777784Electronic) 0167-7659 (Linking)

  50. J. Mc Lean, 1916The thromboplastic action of cephalin. American Journal of Physiology, 41250257

  51. H. Q. Miao, M. Elkin, E. Aingorn, R. Ishai-Michaeli, C. A. Stein, I. Vlodavsky, 1999Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer, 833424431Print) 0020-7136 (Linking)

  52. K. Mizutari, T. Ono, K. Ikeda, K. Kayashima, S. Horiuchi, 1997Photo-enhanced modification of human skin elastin in actinic elastosis by N(epsilon)-(carboxymethyl)lysine, one of the glycoxidation products of the Maillard reaction. J Invest Dermatol, 1085797802X (Print) 0022-202X (Linking)

  53. O. I. , L. Otvos, T. Kieber-Emmons, M. Blaszczyk-Thurin, 2002Role of SA-Le(a) and E-selectin in metastasis assessed with peptide antagonist. Peptides, 2359991010Print) 0196-9781 (Linking)

  54. K. Ono, M. Ishihara, K. Ishikawa, Y. Ozeki, H. Deguchi, M. Sato, H. Hashimoto, Y. Saito, H. Yura, A. Kurita, T. Maehara, 2002Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung. Br J Cancer, 861118031812Print) 0007-0920 (Linking)

  55. V. V. Orlova, E. Y. Choi, C. Xie, E. Chavakis, A. Bierhaus, E. Ihanus, C. M. Ballantyne, C. G. Gahmberg, M. E. Bianchi, P. P. Nawroth, T. Chavakis, 2007A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J, 26411291139Print) 0261-4189 (Linking)

  56. D. L. Ornstein, L. R. Zacharski, 1999The use of heparin for treating human malignancies. Haemostasis, 29Suppl S1,4860Print) 0301-0147 (Linking)

  57. I. Poser, M. Golob, R. Buettner, A. K. Bosserhoff, 2003Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype. Mol Cell Biol, 23829912998Print) 0270-7306 (Linking)

  58. N. V. Rao, B. Argyle, X. Xu, P. R. Reynolds, J. M. Walenga, M. Prechel, G. D. Prestwich, Arthur. R. B. Mac, B. B. Walters, J. R. Hoidal, T. P. Kennedy, 2010Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Physiol Cell Physiol, 2991C97110Electronic) 0363-6143 (Linking)

  59. H. Rauvala, R. Pihlaskari, 1987Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem, 262341662516635Print) 0021-9258 (Linking)

  60. H. Rauvala, A. Rouhiainen, 2010Physiological and pathophysiological outcomes of the interactions of HMGB1 with cell surface receptors. Biochim Biophys Acta, 17991-2164170Print) 0006-3002 (Linking)

  61. S. Reddy, J. Bichler, K. J. Wells-Knecht, S. R. Thorpe, J. W. Baynes, 1995N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry, 34341087210878Print) 0006-2960 (Linking)

  62. A. Saha, Y. C. Lee, Z. Zhang, G. Chandra, S. B. Su, A. B. Mukherjee, 2010Lack of an endogenous anti-inflammatory protein in mice enhances colonization of B16F10 melanoma cells in the lungs. J Biol Chem, 285141082210831X (Electronic) 0021-9258 (Linking)

  63. I. Salama, P. S. Malone, F. Mihaimeed, J. L. Jones, 2008A review of the S100 proteins in cancer. Eur J Surg Oncol, 344357364Electronic) 0748-7983 (Linking)

  64. T. Sasahira, Y. Akama, K. Fujii, H. Kuniyasu, 2005Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch, 4464411415Print) 0945-6317 (Linking)

  65. T. Sasahira, T. Kirita, N. Oue, U. K. Bhawal, K. Yamamoto, K. Fujii, H. Ohmori, Y. Luo, W. Yasui, A. K. Bosserhoff, H. Kuniyasu, 2008High mobility group box-1-inducible melanoma inhibitory activity is associated with nodal metastasis and lymphangiogenesis in oral squamous cell carcinoma. Cancer Sci, 99918061812Electronic) 1347-9032 (Linking)

  66. P. Scaffidi, T. Misteli, M. E. Bianchi, 2002Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature, 4186894191195Print) 0028-0836 (Linking)

  67. A. M. Schmidt, M. Vianna, M. Gerlach, J. Brett, J. Ryan, J. Kao, C. Esposito, H. Hegarty, W. Hurley, M. Clauss, et al.1992Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem, 267211498714997Print) 0021-9258 (Linking)

  68. A. M. Schmidt, S. D. Yan, S. F. Yan, D. M. Stern, 2001The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest, 1087949955Print) 0021-9738 (Linking)

  69. K. Sebekova, Z. Wagner, N. Schupp, P. Boor, 2007Genomic damage and malignancy in end-stage renal failure: do advanced glycation end products contribute? Kidney Blood Press Res, 3015666Print) 1420-4096 (Linking)

  70. G. P. Sims, D. C. Rowe, S. T. Rietdijk, R. Herbst, A. J. Coyle, 2010HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol, 28367388Electronic) 0732-0582 (Linking)

  71. S. M. Smorenburg, P. Griffini, A. B. Tiggelman, A. F. Moorman, W. Boers, J. F. Van Noorden, 1996alpha2-Macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver. Hepatology, 233560570Print) 0270-9139 (Linking)

  72. L. J. Sparvero, D. Asafu-Adjei, R. Kang, D. Tang, N. Amin, J. Im, R. Rutledge, B. Lin, A. A. Amoscato, H. J. Zeh, M. T. Lotze, 2009RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med, 7Electronic) 1479-5876 (Linking)

  73. J. L. Stevenson, S. H. Choi, A. Varki, 2005Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res, 1119Pt 1, 70037011Print) 1078-0432 (Linking)

  74. J. L. Stevenson, A. Varki, L. Borsig, 2007Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects. Thromb Res, 120Suppl 2,S107S111Print) 0049-3848 (Linking)

  75. A. Taguchi, D. C. Blood, G. del Toro, A. Canet, D. C. Lee, W. Qu, N. Tanji, Y. Lu, E. Lalla, C. Fu, M. A. Hofmann, T. Kislinger, M. Ingram, A. Lu, H. Tanaka, O. Hori, S. Ogawa, D. M. Stern, A. M. Schmidt, 2000Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature, 4056784354360Print) 0028-0836 (Linking)

  76. D. Tang, R. Kang, H. J. Zeh, 3rd , M. T. Lotze, 2010High-mobility group box 1 and cancer. Biochim Biophys Acta, 17991-2131140Print) 0006-3002 (Linking)

  77. V. H. Thourani, S. S. Brar, T. P. Kennedy, L. R. Thornton, J. A. Watts, R. S. Ronson, Z. Q. Zhao, A. L. Sturrock, J. R. Hoidal, J. Vinten-Johansen, 2000Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol, 2786H2084H2093Print) 0363-6135 (Linking)

  78. J. W. van Heijst, H. W. Niessen, K. Hoekman, C. G. Schalkwijk, 2005Advanced glycation end products in human cancer tissues: detection of Nepsilon-(carboxymethyl)lysine and argpyrimidine. Ann N Y Acad Sci, 1043725733Print) 0077-8923 (Linking)

  79. A. Varki, 2007Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood, 110617231729Print) 0006-4971 (Linking)

  80. I. Vlodavsky, G. Abboud-Jarrous, M. Elkin, A. Naggi, B. Casu, R. Sasisekharan, N. Ilan, 2006The impact of heparanese and heparin on cancer metastasis and angiogenesis. Pathophysiol Haemost Thromb, 351-2116127Print) 1424-8832 (Linking)

  81. I. Vlodavsky, M. Mohsen, O. Lider, C. M. Svahn, H. P. Ekre, M. Vigoda, R. Ishai-Michaeli, T. Peretz, 1994Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis, 141-6290302Print) 0251-1789 (Linking)

  82. M. Wahrenbrock, L. Borsig, D. Le , N. Varki, A. Varki, 2003Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest, 1126853862Print) 0021-9738 (Linking)

  83. L. Wang, J. R. Brown, A. Varki, J. D. Esko, 2002Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest, 1101127136Print) 0021-9738 (Linking)

  84. M. Wei, G. Tai, Y. Gao, N. Li, B. Huang, Y. Zhou, S. Hao, X. Zeng, 2004Modified heparin inhibits P-selectin-mediated cell adhesion of human colon carcinoma cells to immobilized platelets under dynamic flow conditions. J Biol Chem, 279282920229210Print) 0021-9258 (Linking)

  85. A. Wellstein, G. Zugmaier, J. A. Califano, F. 3rd Kern, S. Paik, M. E. Lippman, 1991Tumor growth dependent on Kaposi’s sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst, 8310716720Print) 0027-8874 (Linking)

  86. Y. Yamamoto, S. Yamagishi, C. C. Hsu, H. Yamamoto, 1996Advanced glycation endproducts-receptor interactions stimulate the growth of human pancreatic cancer cells through the induction of platelet-derived growth factor-B. Biochem Biophys Res Commun, 2223700705X (Print) 0006-291X (Linking)

  87. G. W. Yip, M. Smollich, M. Gotte, 2006Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther, 5921392148Print) 1535-7163 (Linking)

  88. Y. Yoshitomi, H. Nakanishi, Y. Kusano, S. Munesue, K. Oguri, M. Tatematsu, I. Yamashina, M. Okayama, 2004Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Lett, 2072165174Print) 0304-3835 (Linking)

  89. H. Zill, S. Bek, T. Hofmann, J. Huber, O. Frank, M. Lindenmeier, B. Weigle, H. F. Erbersdobler, S. Scheidler, A. E. Busch, V. Faist, 2003RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun, 3002311315X (Print) 0006-291X (Linking)

  90. H. Zill, R. Gunther, H. F. Erbersdobler, U. R. Folsch, V. Faist, 2001RAGE expression and AGE-induced MAP kinase activation in Caco-2 cells. Biochem Biophys Res Commun, 288511081111X (Print) 0006-291X (Linking)

  91. G. Zugmaier, M. E. Lippman, A. Wellstein, 1992Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst, 842217161724Print) 0027-8874 (Linking)